---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053817"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2026-08-06T11:01:44+00:00"
generated_at: "2026-08-06T11:07:16.345063+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics Q2 2026 net loss narrows to $7.2M; cash runway into H1 2028

## Summary
- Net loss of $7.2M vs $17.9M in Q2 2025; collaboration revenue $16.1M (up from $7.6M) due to catch-up adjustment.
- Cash, equivalents, and marketable securities $167.6M; runway into first half of 2028.
- FHD-909 Phase 1 trial in SMARCA4-mutant NSCLC advancing; combination with anti-PD-1 shows complete tumor regression in preclinical models.
- Selective EP300 degrader program targeting IND in 2027 for multiple myeloma and DLBCL; preclinical data outperforms clinical benchmark.
- CBPd-171 timeline delayed due to operational issue at third-party CRO; updated guidance pending.

## SEC filing metadata
- accession: 0001628280-26-053817
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2026-08-06T11:01:44+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828026053817/0001628280-26-053817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828026053817/fhtx-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053817
- JSON: https://secwatch.observer/filing/0001628280-26-053817.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053817.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.